Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment
Open Access
- 30 May 2015
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 444
Abstract
The mechanisms allowing residual multiple myeloma (MM) cells to persist after bortezomib (Bz) treatment remain unclear. We hypothesized that studying the biology of bortezomib-surviving cells may reveal markers to identify these cells and survival signals to target and kill residual MM cells. We used H2B-GFP label retention, biochemical tools and in vitro and in vivo experiments to characterize growth arrest and the unfolded protein responses in quiescent Bz-surviving cells. We also tested the effect of a demethylating agent, 5-Azacytidine, on Bz-induced quiescence and whether inhibiting the chaperone GRP78/BiP (henceforth GRP78) with a specific toxin induced apoptosis in Bz-surviving cells. Finally, we used MM patient samples to test whether GRP78 levels might associate with disease progression. Statistical analysis employed t-test and Mann-Whitney tests at a 95% confidence. We report that Bz-surviving MM cells in vitro and in vivo enter quiescence characterized by p21CIP1 upregulation. Bz-surviving MM cells also downregulated CDK6, Ki67 and P-Rb. H2B-GFP label retention showed that Bz-surviving MM cells are either slow-cycling or deeply quiescent. The Bz-induced quiescence was stabilized by low dose (500nM) of 5-azacytidine (Aza) pre-treatment, which also potentiated the initial Bz-induced apoptosis. We also found that expression of GRP78, an unfolded protein response (UPR) survival factor, persisted in MM quiescent cells. Importantly, GRP78 downregulation using a specific SubAB bacterial toxin killed Bz-surviving MM cells. Finally, quantification of Grp78high/CD138+ MM cells from patients suggested that high levels correlated with progressive disease. We conclude that Bz-surviving MM cells display a GRP78HIGH/p21HIGH/CDK6LOW/P-RbLOW profile, and these markers may identify quiescent MM cells capable of fueling recurrences. We further conclude that Aza + Bz treatment of MM may represent a novel strategy to delay recurrences by enhancing Bz-induced apoptosis and quiescence stability.Keywords
This publication has 32 references indexed in Scilit:
- Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneityBlood, 2013
- The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancerInternational Journal of Cancer, 2013
- Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in MyelomaMolecular Cancer Therapeutics, 2012
- Glucose-Regulated Protein 78 Positivity as a Predictor of Poor Survival in Patients with Renal Cell CarcinomaUrologia Internationalis, 2011
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromesCancer, 2011
- DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancerWIREs Mechanisms of Disease, 2010
- The Role of Maintenance Therapy in the Treatment of Multiple MyelomaJournal of the National Comprehensive Cancer Network, 2010
- A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cellsCancer Chemotherapy and Pharmacology, 2009
- Genetic Models to Study Quiescent Stem Cells and Their NichesAnnals of the New York Academy of Sciences, 2009
- Proteasome Inhibition As a Novel Therapeutic Target in Human CancerJournal of Clinical Oncology, 2005